HOOK vs. GRTS, NTGN, REPL, QTTB, NBTX, URGN, ANRO, RVNC, KMDA, and FBLG
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Gritstone bio (GRTS), Neon Therapeutics (NTGN), Replimune Group (REPL), Q32 Bio (QTTB), Nanobiotix (NBTX), UroGen Pharma (URGN), Alto Neuroscience (ANRO), Revance Therapeutics (RVNC), Kamada (KMDA), and FibroBiologics (FBLG). These companies are all part of the "medical" sector.
Hookipa Pharma (NASDAQ:HOOK) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
Hookipa Pharma has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Gritstone bio received 54 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 69.60% of users gave Hookipa Pharma an outperform vote while only 69.46% of users gave Gritstone bio an outperform vote.
Hookipa Pharma has a net margin of -88.73% compared to Gritstone bio's net margin of -926.13%. Hookipa Pharma's return on equity of -33.33% beat Gritstone bio's return on equity.
Hookipa Pharma has higher revenue and earnings than Gritstone bio. Hookipa Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Hookipa Pharma had 3 more articles in the media than Gritstone bio. MarketBeat recorded 5 mentions for Hookipa Pharma and 2 mentions for Gritstone bio. Hookipa Pharma's average media sentiment score of 0.59 beat Gritstone bio's score of 0.00 indicating that Hookipa Pharma is being referred to more favorably in the media.
63.9% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 3.3% of Hookipa Pharma shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Hookipa Pharma presently has a consensus target price of $5.00, suggesting a potential upside of 510.50%. Gritstone bio has a consensus target price of $4.75, suggesting a potential upside of 537.07%. Given Gritstone bio's higher probable upside, analysts clearly believe Gritstone bio is more favorable than Hookipa Pharma.
Summary
Hookipa Pharma beats Gritstone bio on 11 of the 17 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
